Search PubMed⌕ Search

Biomedical subjects

R Dahl

Publications and source records attributed to R Dahl.

290 records · Page 17Linked to original sources
PubMedDate not supplied

Characteristics of mold allergy.

The sensitization of three common species of molds (C. herbarum, A. alternaria, A. fumigatus) and other common inhalation allergens was studied by SPT (skin prick testing) and RAST in 677 asthmatic patients. Ten percent of patients had an SPT with a mean diameter of at least 2 mm, and 5% had a positive RAST (>0.35 PRU/l) to at least one mold species. A positive RAST was most strongly associated with a positive RAST to animals (odds ratio 9.5) and less positively with a positive RAST to house dust mites (odds ratio 3.9) and storage mites (odds ratio 1.8). Sensitization to mites was significantly associated with indices of damp dwellings, whereas sensitization to molds was not. This study suggests that sensitization to molds mostly occurs in patients with a high potential for being sensitized to common inhalation allergens and that sensitization to molds is not related to damp dwellings.

Alternaria↗
PubMedDate not supplied

Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate.

The study was designed to test for equivalence of asthma control between a new aerosol formulation of beclomethasone dipropionate (BDP) incorporating a chlorofluorocarbon-(CFC) free, hydrofluoroalkane propellant (HFA-134a) and the conventional beclomethasone aerosol formulated in CFC propellants. Sixty-eight asthmatic patients entered an eight-week, randomised, double-blind crossover study. All patients, previously stabilised on BDP, were randomised to receive the same dose of BDP from each of the study treatments. Statistically significant equivalence was demonstrated between HFA-BDP and CFC-BDP for asthma control parameters: FEV1, morning and evening PEF, sleep disturbance, wheeze and cough, morning breathlessness and bronchodilator use. Such equivalence was also demonstrated for safety parameters. To conclude, it has been demonstrated that HFA-BDP achieves a level of asthma control that is clinically and statistically equivalent to CFC-BDP in terms of efficacy and safety, at total daily doses ranging from 200 micrograms to 600 micrograms in asthma patients previously stabilised on inhaled CFC-BDP.

Adolescent↗